Premium
Long‐term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy *
Author(s) -
Skorupski K. A.,
Rodriguez C. O.,
Krick E. L.,
Clifford C. A.,
Ward R.,
Kent M. S.
Publication year - 2009
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2009.00186.x
Subject(s) - histiocytic sarcoma , medicine , chemotherapy , adjuvant therapy , adjuvant , sarcoma , metastasis , distant metastasis , surgery , histiocyte , gastroenterology , oncology , pathology , cancer
Histiocytic sarcoma (HS) is associated with a poor prognosis owing to the presence of metastasis at the time of diagnosis in most dogs. Improved outcome has been reported in several dogs with localized HS following local therapy, however, distant metastasis occurs in 70–91% of dogs suggesting that adjuvant systemic therapy is necessary. The purpose of this retrospective study was to describe clinical characteristics and outcome in dogs with localized HS treated with aggressive local therapy plus adjuvant CCNU chemotherapy. Data from 16 dogs were evaluated. The median disease‐free interval was 243 days. Two dogs had local recurrence and eight dogs developed metastatic disease with a median time to relapse of 201 days in these 10 dogs. The median survival time for all 16 dogs was 568 days. These results support the recommendation for aggressive local therapy combined with adjuvant CCNU chemotherapy in dogs with localized HS.